文献速递精神分裂症与精神病性障碍心境障碍

氯氮平在精神病性、情感性和人格障碍中的跨诊断有效性与安全性:全国性及荟萃分析比较

Transdiagnostic effectiveness and safety of clozapine in individuals with psychotic, affective, and personality disorders: nationwide and meta-analytic comparisons with other antipsychotics.
PubMed 文献 · Lancet Psychiatry · 2025-11-02

结果显示,除边缘型人格障碍外,氯氮平与所有研究障碍的精神科住院风险降低相关,且未增加全因住院或死亡风险。

要点

  • 氯氮平与精神分裂症、分裂情感性障碍、妄想障碍、重性抑郁障碍、精神病性抑郁和双相障碍的精神科住院风险降低相关。
  • 除边缘型人格障碍外,氯氮平使用者的全因停药率低于奥氮平使用者。
  • 氯氮平未增加所有研究障碍的全因住院或死亡风险。

核心结论

  • 研究支持氯氮平在精神分裂症谱系障碍、双相障碍和严重抑郁中的跨诊断有效性和安全性。

研究设计与样本

  • 采用个体内设计,每名患者作为自身对照,数据分国家分析后采用荟萃分析方法合并。

主要发现

  • 在所有研究障碍中,未发现氯氮平使用与全因住院或死亡风险增加相关。
  • 除边缘型人格障碍外,所有研究障碍中氯氮平使用者的全因停药率低于奥氮平使用者。
  • 在双相障碍中,氯氮平在全因精神科住院方面优于心境稳定剂,并在多个障碍特异性结局上优于其他抗精神病药。

临床怎么用

  • 对于精神分裂症谱系障碍、双相障碍和严重抑郁患者,氯氮平可作为跨诊断的有效治疗选择。
  • 临床决策中可参考氯氮平相对于其他口服抗精神病药在降低精神科住院风险方面的优势。

局限性

  • 研究未涉及有生活经验者的参与。
  • 种族数据不可用。
  • 边缘型人格障碍和妄想障碍的部分数据仅来自瑞典。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pharmacotherapy with clozapine is listed as an optional treatment for several psychiatric disorders in guidelines across the globe. Nonetheless, its transdiagnostic effectiveness across most psychiatric disorders remains uncertain due to scant evidence. We therefore aimed to assess the effectiveness and safety of clozapine across multiple psychiatric disorders. METHODS: This cohort study used nationwide register-based data from Finland and Sweden in individuals aged 16 years or older diagnosed with schizophrenia, schizoaffective disorder, delusional disorder, bipolar disorder, psychotic depression, major depressive disorder, and borderline personality disorder (BPD). The effectiveness of clozapine was compared with other oral antipsychotics as a group, and for bipolar disorder additionally against mood stabilisers. The primary outcome was all-cause psychiatric hospitalisation. Secondary outcomes were all-cause hospitalisation or mortality as a composite outcome, all-cause discontinuation (for which clozapine use was compared with olanzapine use), and disorder-specific hospitalisations (eg, hospitalisation due to psychosis for schizophrenia-spectrum disorders and hospitalisation due to mood episodes for affective disorders). A within-individual design was used, where each patient served as their own control, minimising selection bias. Data were analysed separately in each country and combined using meta-analytical methods. People with lived experience were not involved in the research and writing process. FINDINGS: The study population included 505 474 individuals, of whom 283 809 (56·1%) were women and 221 665 (43·9%) were men, with a mean age of 41·6 years (SD 4·4). Data on ethnicity were unavailable. Altogether, clozapine was used by 19 910 individuals. Parsed by disorder, clozapine was used by 12·2-18·7% (n=5258 in Sweden, 10 115 in Finland) of people with schizophrenia, 8·8-20·7% (n=1131, n=1591) with schizoaffective disorder, 1·8% (n=341; data only available in Sweden) with delusional disorder, 0·5% (n=118, n=331) with major depressive disorder, 0·5-0·6% (n=490, n=371) with bipolar disorder, 0·3-0·6% (n=39, n=111) with psychotic depression, and 0·3% (n=36; data only available in Sweden) with BPD. Clozapine use was associated with reduced psychiatric hospitalisation risks versus other oral antipsychotics in all disorders, except for BPD. The greatest reductions were observed in schizophrenia (meta-analysis of adjusted hazard ratios [maHR] 0·70 [95% CI 0·67-0·72]) and schizoaffective disorder (maHR 0·71 [0·67-0·74]), followed by delusional disorder (adjusted hazard ratio 0·73 [0·60-0·89]), major depressive disorder (maHR 0·74 [0·66-0·84]), psychotic depression (maHR 0·76 [0·61-0·96]), and bipolar disorder (maHR 0·77 [0·69-0·87]). Moreover, we found no evidence of increased all-cause hospitalisation or mortality risks associated with clozapine use for all disorders examined. Furthermore, for all disorders studied except for BPD, all-cause discontinuation rates were lower during clozapine than olanzapine use. For bipolar disorder, clozapine outperformed mood stabilisers on all-cause psychiatric hospitalisation and other antipsychotics for several disorder-specific outcomes. INTERPRETATION: These findings support the transdiagnostic effectiveness and safety of clozapine, particularly in schizophrenia-spectrum disorders, bipolar disorder, and severe depression. Given the overall consistent findings across two large national cohorts, these results could inform several treatment guidelines and clinical decision-making for individuals with such severe psychiatric disorders. FUNDING: Sigrid Jusélius Foundation.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Luykx JJ, Colgan M, Vieta E, et al. Transdiagnostic effectiveness and safety of clozapine in individuals with psychotic, affective, and personality disorders: nationwide and meta-analytic comparisons with other antipsychotics. Lancet Psychiatry. 2025. PMID: 41192460. doi:10.1016/S2215-0366(25)00297-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。